mitomycin has been researched along with Cancer of Prostate in 60 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 9.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "To examine the use of Direct Visual Internal Urethrotomy with Mitomycin-C (DVIU-MMC) for bladder neck contracture and vesicourethral anastomotic stenosis in men who have undergone treatment for prostate cancer with radical prostatectomy and/or radiation therapy." | 8.12 | Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment. ( Hacker, EC; Maganty, A; Pere, MM; Rusilko, PJ, 2022) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 5.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "To examine the use of Direct Visual Internal Urethrotomy with Mitomycin-C (DVIU-MMC) for bladder neck contracture and vesicourethral anastomotic stenosis in men who have undergone treatment for prostate cancer with radical prostatectomy and/or radiation therapy." | 4.12 | Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment. ( Hacker, EC; Maganty, A; Pere, MM; Rusilko, PJ, 2022) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| " A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8." | 3.72 | Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. ( Hausladen, DA; Sheryka, E; Weiss, RM; Wheeler, MA, 2003) |
| "Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil." | 3.67 | [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987) |
| "Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate." | 3.66 | [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "In the past 20 years, 3,500 prostate cancer patients have been recruited in 16 phase III trials in untreated and advanced disease and in seven phase II trials in hormone-refractory, metastatic disease." | 2.69 | European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. ( Denis, L, 1998) |
| "Mitomycin C was administered every 6 weeks and treatment was continued as long as tolerance and patient compliance allowed, and no progression was observed." | 2.69 | Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. ( de Reijke, TM; Keuppens, FI; Kliment, J; Rea, LA; Robinson, MR; Sylvester, RJ; Whelan, P, 1999) |
| " Interim analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchidectomy alone (P = ." | 2.68 | Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; Van Poppel, H; Vandenbroucke, F; Vanuytsel, L, 1995) |
| "Mitomycin C 12 mg/m2 was given every 5 weeks starting on day 14." | 2.67 | Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study. ( de Wet, M; Falkson, G; Lotz, BP; Potgieter, HC; Raats, JI; Rapoport, BL, 1993) |
| " Preliminary analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchiectomy alone (p = 0." | 2.67 | Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; van den Broucke, F; Van Poppel, H; van Uytsel, L, 1993) |
| " It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups." | 2.65 | Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials. ( Schroeder, FH, 1984) |
| "Therefore, the fact that tumors do not develop in the majority of the population during their lifetime indicates the existence of other defense system(s)." | 1.35 | Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines ( Kulcsár, G, 2009) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | 1.32 | Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| "Mimosine treatment resulted in upregulation of p27(Kip1) and P-gp, whereas p21(WAF-1) remained unchanged." | 1.31 | Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. ( Fischer, K; Hescheler, J; Sauer, H; Wartenberg, M, 2002) |
| " CGP 69846A, in combination with cisplatin, showed superadditive antitumor effects against PC3 human prostate carcinomas with tumor cures, and in combination with mitomycin C, superadditive antitumor effects of CGP 69846A with tumor cures against NCI-H460 large cell lung carcinoma were found." | 1.30 | Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. ( Fabbro, D; Geiger, T; Monia, BP; Müller, M, 1997) |
| "Mitomycin C has proved to be useful as prophylaxis against superficial bladder tumor recurrences." | 1.27 | Prostatic recurrences in the management of superficial bladder tumors. ( Bondhus, MJ; Chaikin, L; Lockhart, JL; Politano, VA, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (33.33) | 18.7374 |
| 1990's | 18 (30.00) | 18.2507 |
| 2000's | 15 (25.00) | 29.6817 |
| 2010's | 6 (10.00) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hacker, EC | 1 |
| Maganty, A | 1 |
| Pere, MM | 1 |
| Rusilko, PJ | 1 |
| Patil, Y | 1 |
| Shmeeda, H | 1 |
| Amitay, Y | 1 |
| Ohana, P | 1 |
| Kumar, S | 1 |
| Gabizon, A | 1 |
| Bazan, JG | 1 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 1 |
| Kapp, DS | 1 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Jin, L | 1 |
| Li, C | 1 |
| Li, R | 1 |
| Sun, Z | 1 |
| Fang, X | 1 |
| Li, S | 1 |
| Carmona, R | 1 |
| Pritz, J | 1 |
| Bydder, M | 1 |
| Gulaya, S | 1 |
| Zhu, H | 1 |
| Williamson, CW | 1 |
| Welch, CS | 1 |
| Vaida, F | 1 |
| Bydder, G | 1 |
| Mell, LK | 1 |
| Kulcsár, G | 1 |
| Pakkanen, S | 1 |
| Wahlfors, T | 1 |
| Siltanen, S | 1 |
| Patrikainen, M | 1 |
| Matikainen, MP | 1 |
| Tammela, TL | 1 |
| Schleutker, J | 1 |
| Saif, MW | 1 |
| Dai, T | 1 |
| Niranjan, B | 1 |
| Lawrence, MG | 1 |
| Papargiris, MM | 1 |
| Richards, MG | 1 |
| Hussain, S | 1 |
| Frydenberg, M | 1 |
| Pedersen, J | 1 |
| Taylor, RA | 1 |
| Risbridger, GP | 1 |
| Bagley, CM | 1 |
| Lane, RF | 1 |
| Blasko, JC | 1 |
| Grimm, PD | 1 |
| Ragde, H | 1 |
| Cobb, OE | 1 |
| Rowbotham, RK | 1 |
| Sheryka, E | 1 |
| Wheeler, MA | 1 |
| Hausladen, DA | 1 |
| Weiss, RM | 1 |
| Papo, N | 1 |
| Shai, Y | 1 |
| Jenkins, DE | 1 |
| Oei, Y | 1 |
| Hornig, YS | 1 |
| Yu, SF | 1 |
| Dusich, J | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Van Der Heijden, MS | 1 |
| Brody, JR | 1 |
| Kern, SE | 1 |
| Hod, Y | 1 |
| Nilsson, S | 1 |
| Strang, P | 1 |
| Ginman, C | 1 |
| Zimmermann, R | 1 |
| Edgren, M | 1 |
| Nordström, B | 1 |
| Ryberg, M | 1 |
| Kälkner, KM | 1 |
| Westlin, JE | 1 |
| Cummings, M | 1 |
| Higginbottom, K | 1 |
| McGurk, CJ | 1 |
| Wong, OG | 1 |
| Köberle, B | 1 |
| Oliver, RT | 1 |
| Masters, JR | 1 |
| Zhang, X | 1 |
| Ling, MT | 1 |
| Wong, YC | 1 |
| Wang, X | 1 |
| Schroeder, FH | 1 |
| deKernion, JB | 1 |
| Lindner, A | 1 |
| Lockhart, JL | 1 |
| Chaikin, L | 1 |
| Bondhus, MJ | 1 |
| Politano, VA | 1 |
| Nemoto, R | 1 |
| Mori, H | 1 |
| Abe, R | 2 |
| Kato, T | 3 |
| Harada, M | 1 |
| Ishida, K | 1 |
| Chiba, R | 2 |
| Shindo, M | 1 |
| Kato, H | 1 |
| Burk, K | 3 |
| Gropp, C | 2 |
| Rodeck, G | 1 |
| Logothetis, CJ | 1 |
| Samuels, ML | 1 |
| von Eschenbach, AC | 1 |
| Trindade, A | 1 |
| Ogden, S | 1 |
| Grant, C | 1 |
| Johnson, DE | 1 |
| Babaian, RJ | 1 |
| Hsu, SD | 1 |
| Kasimis, BS | 2 |
| Moran, EM | 2 |
| Miller, JB | 2 |
| Forbes, KA | 2 |
| Kaneshiro, CA | 2 |
| Poblet, MT | 1 |
| Williams, JL | 1 |
| Vandenbroucke, F | 1 |
| Van Poppel, H | 2 |
| Derluyn, J | 2 |
| Popelier, G | 2 |
| Casselman, J | 2 |
| Billiet, I | 2 |
| Vanuytsel, L | 1 |
| Paridaens, R | 2 |
| Baert, L | 2 |
| Kakinuma, H | 1 |
| Sato, K | 3 |
| Miura, K | 1 |
| Sasaki, S | 2 |
| Lenci, G | 1 |
| Müller-Quernheim, J | 1 |
| Lorenz, J | 1 |
| Schweden, F | 1 |
| Ferlinz, R | 1 |
| Newling, DW | 2 |
| Fossa, SD | 2 |
| Tunn, UW | 1 |
| Kurth, KH | 2 |
| de Pauw, M | 2 |
| Sylvester, R | 2 |
| Verbaeys, A | 1 |
| Carpentier, P | 1 |
| Cuvelier, C | 1 |
| Praet, M | 1 |
| Fonteyne, E | 1 |
| Morelle, V | 1 |
| De Sy, WA | 1 |
| Blumenstein, B | 1 |
| Crawford, ED | 1 |
| Saiers, JH | 1 |
| Stephens, RL | 1 |
| Rivkin, SE | 1 |
| Coltman, CA | 1 |
| Rapoport, BL | 1 |
| Falkson, G | 1 |
| Raats, JI | 1 |
| de Wet, M | 1 |
| Lotz, BP | 1 |
| Potgieter, HC | 1 |
| van den Broucke, F | 1 |
| van Uytsel, L | 1 |
| Komatsu, H | 1 |
| Denis, L | 1 |
| Kurdistani, SK | 1 |
| Arizti, P | 1 |
| Reimer, CL | 1 |
| Sugrue, MM | 1 |
| Aaronson, SA | 1 |
| Lee, SW | 1 |
| Geiger, T | 1 |
| Müller, M | 1 |
| Monia, BP | 1 |
| Fabbro, D | 1 |
| de Reijke, TM | 1 |
| Keuppens, FI | 1 |
| Whelan, P | 1 |
| Kliment, J | 2 |
| Robinson, MR | 2 |
| Rea, LA | 2 |
| Sylvester, RJ | 1 |
| Curran, D | 2 |
| Aaronson, NK | 1 |
| Keuppens, F | 1 |
| DeReijke, TM | 1 |
| Hetherington, J | 1 |
| Kil, PJ | 1 |
| Recchia, F | 1 |
| Sica, G | 1 |
| De Filippis, S | 1 |
| Rosselli, M | 1 |
| Pompili, PL | 1 |
| Rea, S | 1 |
| Van Steen, K | 1 |
| Molenberghs, G | 1 |
| Wartenberg, M | 1 |
| Fischer, K | 1 |
| Hescheler, J | 1 |
| Sauer, H | 1 |
| Dik, P | 1 |
| Blom, JH | 1 |
| Schröder, FH | 1 |
| Laurie, JA | 1 |
| Hahn, RG | 1 |
| Therneau, TM | 1 |
| Patel, SR | 1 |
| Mailliard, JA | 1 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Morton, RF | 1 |
| Krook, JE | 1 |
| Weissbach, L | 1 |
| Solsona, E | 1 |
| Iborra, I | 1 |
| Ricós, JV | 1 |
| Monrós, JL | 1 |
| Dumont, R | 1 |
| Casanova, J | 1 |
| Calabuig, C | 1 |
| Fossa, S | 1 |
| Tunn, U | 1 |
| Yoshimoto, J | 2 |
| Ochi, J | 2 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Saegusa, M | 1 |
| Hara, M | 1 |
| Akagi, T | 1 |
| Obama, T | 2 |
| Tsushima, T | 2 |
| Ozaki, Y | 1 |
| Moriyama, M | 1 |
| Tsuchida, S | 1 |
| Matsuo, S | 1 |
| Veronesi, A | 1 |
| Dal Bo, V | 1 |
| Lo Re, G | 1 |
| Della Valentina, M | 1 |
| Tirelli, U | 1 |
| Merlo, A | 1 |
| Talamini, R | 1 |
| Francini, M | 1 |
| Monfardini, S | 1 |
| Portnoĭ, AS | 1 |
| Sropp, C | 1 |
| Schultze-Seemann, W | 1 |
| de Riese, W | 2 |
| Stoter, G | 1 |
| Jones, WG | 2 |
| Toma, H | 1 |
| Nakamura, R | 1 |
| Onitsuka, S | 1 |
| Goya, N | 1 |
| Nakazawa, H | 1 |
| Hardeman, SW | 1 |
| Perry, A | 1 |
| Soloway, MS | 1 |
| Metter, GE | 1 |
| Löbenau, S | 1 |
| Nasu, Y | 1 |
| Matsumura, Y | 1 |
| Ohmori, H | 1 |
4 reviews available for mitomycin and Cancer of Prostate
| Article | Year |
|---|---|
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
[Combined hormone/chemotherapy for advanced prostatic cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyclophosphamide; Diethylstilbestro | 1997 |
[Chemotherapy of prostatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1985 |
Chemotherapy of hormone refractory prostatic cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Mitomycin; Mitomycins; Prostatic Neop | 1988 |
20 trials available for mitomycin and Cancer of Prostate
| Article | Year |
|---|---|
Adjuvant chemohormonal therapy of high risk prostate carcinoma. Ten year results.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineo | 2002 |
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Epirubici | 2005 |
Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Topics: Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; D | 1984 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; Mitomycin; Neoplasm Meta | 1995 |
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
Topics: Aged; Estramustine; Europe; Humans; Male; Middle Aged; Mitomycin; Multivariate Analysis; Prospective | 1993 |
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Male; Mitomycin; Prostatic | 1993 |
Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial.
Topics: Aged; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Mitomycin; Neoplasm Metastasis; Or | 1993 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Disease Progression; Humans; Male; Mitomycin | 1999 |
Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.
Topics: Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Male; Middle Aged; Mitomycin; | 2000 |
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr | 2001 |
Mitomycin C and aminoglutethimide in the treatment of metastatic prostatic cancer: a phase II study.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Humans; | 1992 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
[Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate].
Topics: Epirubicin; Estramustine; Humans; Male; Mitomycin; Prospective Studies; Prostatic Neoplasms | 1992 |
Recurrence of superficial bladder tumors in prostatic urethra.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma in Si | 1991 |
Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no.
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Europe; Humans; Male; Mitomycin; Mitom | 1990 |
Chemotherapy of hormone refractory prostatic cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Mitomycin; Mitomycins; Prostatic Neop | 1988 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
38 other studies available for mitomycin and Cancer of Prostate
| Article | Year |
|---|---|
Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment.
Topics: Constriction, Pathologic; Contracture; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Prostate | 2022 |
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
Topics: Antigens, Surface; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Folic Acid; | 2018 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A₂ and migration in prostate cancer cell RM-1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Corticotropin-Relea | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line | 2009 |
PALB2 variants in hereditary and unselected Finnish prostate cancer cases.
Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Mutational Analysis; Family; Fanc | 2009 |
Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Genes, BRCA2; Humans; Lung Diseases, Interstitial; Male; Mitomyci | 2010 |
Primary culture and propagation of human prostate epithelial cells.
Topics: Animals; Antigens, Surface; Biomarkers; Cell Culture Techniques; Cell Differentiation; Cell Line; Ce | 2013 |
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma.
Topics: Adenocarcinoma; Administration, Intravesical; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; | 2003 |
New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Cell Death; Cell Membrane; Fluoresceins; Hem | 2003 |
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A | 2003 |
Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Fanconi Anemia; Fanconi Anemia Complementation Group D2 | 2004 |
Differential control of apoptosis by DJ-1 in prostate benign and cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Blotting, Western; Cell Line; Cell Line, Tu | 2004 |
XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA Repair; DNA-Binding Proteins; Endonucleases; | 2006 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, | 2007 |
Prostatic recurrences in the management of superficial bladder tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1983 |
[Clinical study on chemo-embolization in malignant urogenital cancer. II. Intra-arterial injection of mitomycin C microcapsules in advanced prostatic cancer].
Topics: Aged; Antibiotics, Antineoplastic; Capsules; Humans; Infusions, Intra-Arterial; Male; Middle Aged; M | 1983 |
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1983 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro | 1984 |
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl | 1983 |
[Chemoembolization with mitomycin C microcapsules (MMC-mc) in the treatment of bone metastases from prostatic and renal cancer].
Topics: Aged; Bone Neoplasms; Capsules; Chemoembolization, Therapeutic; Female; Humans; Kidney Neoplasms; Ma | 1994 |
[Toxic lung damage caused by mitomycin C].
Topics: Aged; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Human | 1994 |
Down-staging prostate cancer. Is it possible by androgen depletion and Mitomycin C therapy?
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Goserelin; Humans; Lymph Node Excision; | 1993 |
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cells, Cultured; Chromoso | 1998 |
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small C | 1997 |
Sensitivity analysis of longitudinal binary quality of life data with drop-out: an example using the EORTC QLQ-C30.
Topics: Antibiotics, Antineoplastic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; | 2001 |
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; C | 2002 |
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A | 1987 |
[Arterial microchemoembolization in the treatment of prostatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Capsules; Cisplatin; Embolization, Therap | 1988 |
Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.
Topics: Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Prostati | 1989 |
Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Fluorouracil; Humans; | 1987 |
Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Combined Modality Therap | 1988 |
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell | 1988 |
EORTC Phase II chemotherapy studies in prostate cancer.
Topics: Drug Evaluation; Humans; Male; Mitomycin; Mitomycins; Prostatic Neoplasms; Vinblastine; Vindesine | 1985 |
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1985 |
[Effect of KW-2083 in Stage D adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Administration Schedule; Humans; Male; Mitomycin; | 1985 |